Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Toxic

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    634 result(s) found for: Toxic. Displaying page 4 of 32.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-000564-28 Sponsor Protocol Number: MO18109 Start Date*: 2004-11-01
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An expanded access program of Tarceva (erlotinib) in patients with advanced stage IIIB/ IV non-small cell lung cancer (NSCLC)
    Medical condition: advanced stage IIIB/ IV non-small cell lung cancer (NSCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) SE (Completed) LV (Completed) AT (Completed) HU (Completed) LT (Completed) IE (Completed) CZ (Completed) IT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004991-31 Sponsor Protocol Number: INCB24360-301/MK3475-252/Keynote252 Start Date*: 2016-05-03
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 ...
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) DK (Completed) IE (Completed) ES (Completed) PL (Completed) FR (Completed) BE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007971-18 Sponsor Protocol Number: LOC/05-12/RENNES Start Date*: 2008-03-18
    Sponsor Name:C.H.U. de RENNES
    Full Title: Evaluation des effets de la 9 alpha fluorohydrocortisone sur la réponse pressive à la noradrénaline, la perfusion gastrique, le débit huméral et la rigidité artérielle dans le choc septique.
    Medical condition: Choc septique.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040070 Septic shock LLT
    9.1 10040580 Shock septic LLT
    9.1 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001613-33 Sponsor Protocol Number: IgM-FAT Start Date*: 2019-04-18
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA
    Full Title: Efficacy and safety of adjunctive IgM-enriched immunoglobulin therapy with a personalized dose based on serum IgM-titers vs. standard dose in patients with septic shock. A multicenter, intervention...
    Medical condition: Septic shock
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10040580 Shock septic LLT
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001568-66 Sponsor Protocol Number: A4061028 Start Date*: 2007-08-27
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA
    Full Title: A randomized, double-blind phase 3 study of gemcitabine plus AG-013736 versus gemcitabine plus placebo for the first-line treatment of patients with locally advanced, unresectable or metastatic pan...
    Medical condition: Unresectable or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033605 Pancreatic cancer metastatic LLT
    9.1 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) SE (Completed) GB (Prematurely Ended) FR (Completed) PT (Completed) AT (Prematurely Ended) HU (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000624-40 Sponsor Protocol Number: CSTI571BDE70 Start Date*: 2010-05-27
    Sponsor Name:University of Heidelberg
    Full Title: PHASE II STUDY TO EVALUATE GLIVEC (IMATINIB MESYLATE) TO INDUCE PROGRESSION ARREST IN AGGRESSIVE FIBROMATOSIS / DESMOID TUMORS NOT AMENABLE TO SURGICAL RESECTION WITH R0 INTENT OR ACCOMPANIED BY UN...
    Medical condition: AGGRESSIVE FIBROMATOSIS / DESMOID TUMORS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005805-66 Sponsor Protocol Number: DEXCAR-0212 Start Date*: 2012-09-21
    Sponsor Name:Unitat de Recerca en Pediatria Nutrició i Desenvolupament Humà
    Full Title: Dexametasona administration in first febrile urinary tract infection episode as renal damage prevention strategy.
    Medical condition: Acute pyelonephritis
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003541-17 Sponsor Protocol Number: FIMHCSBR-2017 Start Date*: 2018-10-24
    Sponsor Name:FIMABIS Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud [...]
    1. FIMABIS Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
    2. APES Costa del Sol (Agencia Pública Empresarial Sanitaria)
    Full Title: Neuropsiquiatric Evolution After Introduction of Raltegravir QD in substitution of dolutegravir: NEAR QD Study
    Medical condition: Human Inmunodeficiency Virus Infection (HIV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000028-34 Sponsor Protocol Number: H3E-MC-JMDB Start Date*: 2004-07-06
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A randomised Phase 3 Trial of ALIMTA and Cisplatin versus GEMZAR and Cisplatin in Patients with locally advanced or metastatic Non-Small-Cell Lung Cancer
    Medical condition: Locally advanced or metastatic Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-017675-16 Sponsor Protocol Number: OFT113725 Start Date*: 2010-11-30
    Sponsor Name:Plymouth Hospitals NHS Trust
    Full Title: Phase II Trial of Single Agent Ofatumumab in Relapsed / Refractory Mantle Cell Lymphoma
    Medical condition: Relapsed or refractory Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026800 Mantle cell lymphoma recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000393-34 Sponsor Protocol Number: R03003 Start Date*: 2015-06-01
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Clinical trial of the investigational medicinal product, local anaesthetic levo-bupivacaine in infants 3 - 6 months post natal age.
    Medical condition: Pain relief in infants undergoing surgical repair of bladder exstrophy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10054799 Perioperative analgesia PT
    18.0 10042613 - Surgical and medical procedures 10036276 Postoperative analgesia PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004520-10 Sponsor Protocol Number: ACNS1021 Start Date*: 2019-06-25
    Sponsor Name:National Cancer Institute (NCI)
    Full Title: 2018-004520-10
    Medical condition: Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-005104-14 Sponsor Protocol Number: UKSH-KI-MolGastro-001 Start Date*: 2007-08-14
    Sponsor Name:Universitätsklinikum Schleswig-Holstein
    Full Title: A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma
    Medical condition: Pancreatic ductal adenocarcinoma, non resectable
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033600 Pancreatic adenocarcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007515-33 Sponsor Protocol Number: Mel-Swe-01 Start Date*: 2009-08-13
    Sponsor Name:SentoClone AB
    Full Title: A multi-centre, two-arm, randomized, open, phase II study of adaptive design investigating SentoClone® compared to reference treatment in advanced malignant melanoma
    Medical condition: Surgically incurable stage III or IV malignant melanoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025670 Malignant melanoma stage III PT
    9.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004803-78 Sponsor Protocol Number: 1.1 Start Date*: 2009-03-20
    Sponsor Name:Imperial College London
    Full Title: Effectiveness of Transtympanic Steroids in unilateral Ménière's disease: a Randomised Controlled Double-Blind Trial
    Medical condition: refractory unilateral Meniere's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000641 Active Meniere's disease, cochleovestibular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021792-81 Sponsor Protocol Number: 2010-12 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
    Full Title: SFCE-Metro 01 : Etude de phase II de chimiothérapie métronomique associant celecoxib-methotrexate-vinblastine-cyclophosphamide chez les enfants porteurs d’une tumeur solide en rechute ou en progre...
    Medical condition: children and adolescents with relapsed or progressing solid tumours.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005135-13 Sponsor Protocol Number: V37_07E1 Start Date*: 2014-11-28
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Phase III Observer blind Single-Coordinating Center Pediatric Study in China Comparing a Booster Dose of Vaxem™ Hib to HIBERIX® When Given as Part of a Local Dosing Regimen in Infants
    Medical condition: Meningitis, epiglottitis, pneumonia, arthritis caused by Haemophilus influenzae type b.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-005364-65 Sponsor Protocol Number: Start Date*: 2007-06-27
    Sponsor Name:AUO
    Full Title: Intermittent Treatment with Taxotere and Prednisone in patients with asymptomatic, hormone-refractory prostate cancer: A Multicenter Phase II Trial
    Medical condition: asymptomatic hormone-refractory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006798-33 Sponsor Protocol Number: MOTOR Start Date*: 2008-11-24
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Medical optimization of TORisel (MoTOR): MULTICENTER, PHASE II EVALUATION OF TORISEL AS II-LINE TREATMENT FOR METASTATIC RCC PATIENTS PROGRESSING AFTER CYTOKINE THERAPY, TYROSINE KINASE, OR ANGIOGE...
    Medical condition: Patients with metastatic RCC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050018 Renal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000510-10 Sponsor Protocol Number: RG_11-141 Start Date*: 2012-10-09
    Sponsor Name:University of Birmingham
    Full Title: A Phase IIa trial of 177 Lutetium Dotatate in Children with Primary Refractory or Relapsed High-Risk Neuroblastoma
    Medical condition: Neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 08:55:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA